An expert discusses how in the first-line (1L) treatment of advanced unresectable hepatocellular carcinoma (uHCC) with tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, proactive ...

resulting in a significant progression-free survival benefit over sorafenib. At present, there is no clear evidence of superiority of either sequence (TKI–TKI or TKI–mTOR) based on both ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors, ...